Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



SCIASCIA THOMAS Create: Alert

All | News | Filings
Date FiledTypeDescription
09/19/2022 4 SCIASCIA THOMAS (Chief Medical Officer) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 7,500 options to buy @ $3.21, valued at $24.1k
07/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/01/2022 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
02/15/2022 4 SCIASCIA THOMAS (Chief Medical Officer) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 110,000 options to buy @ $0.511, valued at $56.2k
02/19/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/18/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/05/2019 4 SCIASCIA THOMAS (Chief Medical Officer) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Granted 50,000 options to buy @ $10.12, valued at $506k
05/13/2019 4 SCIASCIA THOMAS (Chief Medical Officer) has filed a Form 4 on Trevi Therapeutics, Inc.
Txns: Converted 17,118 shares @ $0
Converted 109,015 preferred shares @ $0
Converted 13,410 preferred shares @ $0
05/07/2019 3 SCIASCIA THOMAS (Chief Medical Officer) has filed a Form 3 on Trevi Therapeutics, Inc.
11/08/2010 4 Form 4 - Statement of changes in beneficial ownership of securities
09/22/2010 4 SCIASCIA THOMAS (SVP Clin Dev & Reg Aff & CMO) has filed a Form 4 on PENWEST PHARMACEUTICALS CO
Txns: Unknown transaction of 40,494 shares @ $0
Unknown transaction of 45,500 options to buy @ $2.62, valued at $119.2k
Unknown transaction of 19,500 options to buy @ $3.05, valued at $59.5k
Unknown transaction of 65,000 options to buy @ $1.56, valued at $101.4k
Unknown transaction of 75,000 options to buy @ $3.04, valued at $228k
03/08/2010 4 SCIASCIA THOMAS (SVP Clin Dev & Reg Aff & CMO) has filed a Form 4 on PENWEST PHARMACEUTICALS CO
Txns: Granted 75,000 options to buy @ $3.04, valued at $228k

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy